Car T-Cell Therapy

The basic science discoveries to which Helen E. Heslop, MD, DSc (Hon), has contributed place her firmly on the Mount Rushmore of pioneers in the field of gene and cell therapy.

Follicular lymphoma is among the least common types of non-Hodgkin lymphoma, but the nature of the disease has allowed those who require treatment to benefit from the groundbreaking development of chimeric antigen receptor T cells.

The FDA granted orphan drug designation to KITE-222, an investigational chimeric antigen receptor T-cell therapy, for treatment of adults with relapsed or refractory acute myeloid leukemia.

The FDA granted orphan drug designation to SynKIR-110, an investigational chimeric antigen receptor T-cell therapy, for treatment of mesothelin-expressing mesothelioma.

A chimeric antigen receptor T-cell therapy produced a response rate of 71% among patients with relapsed or refractory multiple myeloma, according to phase 1 study results published in The New England Journal of Medicine.

Prolonged responses to chimeric antigen receptor T-cell therapy for advanced multiple myeloma may depend on the composition of the patient’s post-treatment immune microenvironment, results from a retrospective study showed.

The FDA approval of the first ever chimeric antigen receptor T-cell therapy for multiple myeloma in 2021 laid the groundwork for others to follow.

The last few years have seen major therapeutic advancements in the field of triple-class refractory multiple myeloma.

Unequal distribution of trial sites nationwide has led to inequitable access to cutting-edge immunotherapies among Black patients with advanced multiple myeloma, according to research published in JAMA Network Open.

Researchers who identified proteins that influence T-cell formation have leveraged their discovery to develop a process that boosts the efficacy of chimeric antigen receptor T-cell therapy for solid tumors.